Abstract
Pyrazole scaffold containing compounds have been found to be as enzyme activator or inhibitor in the diabetic disease condition. The pyrazole containing compounds have been found to be activators in case such as glucokinase and as inhibitors in cases such as sodium glucose co-transporter-1, sodium-glucose co-transporter-2, dipeptidyl peptidase-4, glycogen synthase kinase-3beta, Glucagon-stimulated intracellular cAMP formation and 11β-HSD1. Pyrazole containing compounds can also act as competitive antagonist at cannabinoid-1 receptor while agonist at peroxisome proliferatoractivated receptor-α and γ. In present work, the most active pyrazole derivatives have been selected from reported literature along with methods utilized for detection of blood plasma glucose levels or urinary glucose levels as well as assays involving enzyme inhibition or activation at cellular level. The activity values of corresponding pyrazole compounds obtained from synthetic or structural activity relationship studies can be helpful for medicinal chemist to focus design of novel chemical entities containing pyrazole system as a part of antidiabetic drug substance.
Keywords: Pyrazole, antidiabetic, Sodium glucose co- transporter, Peroxisome proliferator-activated receptor, Glycogen synthase kinase, Dipeptidyl peptidase-4.
Letters in Drug Design & Discovery
Title:Development of Pyrazole Compounds as Antidiabetic Agent: A Review
Volume: 11 Issue: 5
Author(s): Prasanna A. Datar and Sonali R. Jadhav
Affiliation:
Keywords: Pyrazole, antidiabetic, Sodium glucose co- transporter, Peroxisome proliferator-activated receptor, Glycogen synthase kinase, Dipeptidyl peptidase-4.
Abstract: Pyrazole scaffold containing compounds have been found to be as enzyme activator or inhibitor in the diabetic disease condition. The pyrazole containing compounds have been found to be activators in case such as glucokinase and as inhibitors in cases such as sodium glucose co-transporter-1, sodium-glucose co-transporter-2, dipeptidyl peptidase-4, glycogen synthase kinase-3beta, Glucagon-stimulated intracellular cAMP formation and 11β-HSD1. Pyrazole containing compounds can also act as competitive antagonist at cannabinoid-1 receptor while agonist at peroxisome proliferatoractivated receptor-α and γ. In present work, the most active pyrazole derivatives have been selected from reported literature along with methods utilized for detection of blood plasma glucose levels or urinary glucose levels as well as assays involving enzyme inhibition or activation at cellular level. The activity values of corresponding pyrazole compounds obtained from synthetic or structural activity relationship studies can be helpful for medicinal chemist to focus design of novel chemical entities containing pyrazole system as a part of antidiabetic drug substance.
Export Options
About this article
Cite this article as:
Datar A. Prasanna and Jadhav R. Sonali, Development of Pyrazole Compounds as Antidiabetic Agent: A Review, Letters in Drug Design & Discovery 2014; 11 (5) . https://dx.doi.org/10.2174/1570180810666131113212354
DOI https://dx.doi.org/10.2174/1570180810666131113212354 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition
Current Vascular Pharmacology Diabetes Case Identification Methods Applied to Electronic Medical Record Systems: Their Use in HIV-Infected Patients
Current HIV Research Diabetes Mellitus and SARS-CoV-2 Infection: Pathophysiologic Mechanisms and Implications in Management
Current Diabetes Reviews Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Current Medicinal Chemistry Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Extracellular Hsp70: Export and Function
Current Protein & Peptide Science Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism Progress in the Diagnosis and Treatment of Pulmonary Aspergillosis
Current Respiratory Medicine Reviews Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry Brittle Type 1 Diabetes Mellitus
Current Medicinal Chemistry CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery EDITORIAL (Thematic Issue: Retinal Neurodegeneration in the Course of Diabetes: Neuroprotection as a Potential Treatment Target)
Current Neuropharmacology The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin
Cardiovascular & Hematological Agents in Medicinal Chemistry Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology